本页面由Tiger Trade Technology Pte. Ltd.提供服务

Tarsus Pharmaceuticals, Inc.

74.40
+1.241.69%
成交量:146.30万
成交额:1.09亿
市值:32.65亿
市盈率:-68.74
高:76.64
开:73.20
低:72.98
收:73.16
52周最高:91.53
52周最低:53.89
股本:4,388.30万
流通股本:3,563.83万
量比:2.41
换手率:4.11%
股息:- -
股息率:- -
每股收益(TTM):-1.0824
每股收益(LYR):-1.5900
净资产收益率:-13.68%
总资产收益率:-5.48%
市净率:9.42
市盈率(LYR):-46.79

数据加载中...

2026/09/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/11

重要事件披露

Form 8-K - Current report
2026/09/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/25

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/13

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/06

重要事件披露

Form 8-K - Current report
2026/08/06

重要事件披露

Form 8-K - Current report
2026/08/06

重要事件披露

Form 8-K - Current report
2026/07/13

重要事件披露

Form 8-K - Current report